JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 7, Pages 961-973
Publisher
Informa Healthcare
Online
2012-05-22
DOI
10.1517/13543784.2012.690029
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib
- (2013) Drugs in research & development
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial
- (2011) BOULOS HARAOUI et al. JOURNAL OF RHEUMATOLOGY
- Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis
- (2011) Ken Garber NATURE BIOTECHNOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
- (2010) Graeme Jones Expert Review of Clinical Immunology
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
- (2010) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Interleukin-6 as a key player in systemic inflammation and joint destruction
- (2009) J.E. Fonseca et al. AUTOIMMUNITY REVIEWS
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Rheumatoid arthritis
- (2009) Lars Klareskog et al. LANCET
- Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
- (2009) Shin-ya Kawashiri et al. RHEUMATOLOGY INTERNATIONAL
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Inteferons pen the JAK–STAT pathway
- (2008) Christian Schindler et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now